中药被认为是一种潜在有效的方法，可治疗因内分泌治疗引起的乳腺癌患者遭受的不良反应。为了研究中药对荷尔蒙受体阳性（HR +）乳腺癌患者内分泌治疗引起的副作用的影响，我们在2022年5月20日之前搜索了10个数据库（例如PubMed、Web of Science、Cochrane图书馆、中国国家知识信息数据库和其他数据库）。搜索词语包括“中药”、“乳腺癌”、“内分泌治疗”、“临床试验”及其Mesh词。两位独立审阅员进行了研究选择和数据提取。使用Cochrane bias风险评价方法来评价偏倚风险。 共纳入2288名患者的31项研究。骨密度（腰椎骨密度（MD 0.08，95％ CI 0.07至0.09，p <0.00001）和股骨颈骨密度（MD 0.08，95％ CI 0.07至0.10，p <0.00001））和骨钙素（BGP）（MD 0.24，95％ CI 0.17至0.31，p <0.00001）有显著改善，甘油三酯显著下降（MD -0.53，95％ CI -1.00至-0.07，p <0.05），雌二醇水平无影响（MD 0.90，95％ CI -0.31至2.12，p = 0.15）。 结果表明，中药结合辅助疗法能够适度减轻内分泌治疗引起的副作用，包括HR +乳腺癌患者的骨质丢失和血脂异常，揭示了中药在治疗（HR +）乳腺癌中的潜在作用。更多高质量的随机对照试验需要进一步验证中药的有效性和安全性。

Chinese medicinal herbs (CMH) have been considered a potentially efficacious approach for patients with breast cancer that experience adverse effects from endocrine treatment.To investigate the impact of CMH on endocrine therapy-induced side effects in patients with hormone receptor-positive (HR+) breast cancer.Ten databases (e.g., PubMed, Web of Science, Cochrane Library, China National Knowledge Information Database and other databases) were searched up to 20 May 2022. The search terms included Chinese herb, breast cancer, endocrine therapy, clinical trial and their mesh terms. The study selection and data extraction were performed by two independent reviewers. The risk of bias was evaluated using the Cochrane risk of bias method.A total of 31 studies with 2288 patients were included. There were significant improvements in bone mineral density (BMD) [lumbar BMD (MD 0.08, 95% CI 0.07 to 0.09, p < 0.00001) and femoral neck BMD (MD 0.08, 95% CI 0.07 to 0.10, p < 0.00001)] and bone gal protein (BGP) (MD 0.24, 95% CI 0.17 to 0.31, p < 0.00001), with a significant reduction in triglycerides (MD -0.53, 95% CI -1.00 to -0.07, p < 0.05) and no effect on estradiol levels (MD 0.90, 95% CI -0.31 to 2.12, p = 0.15).CMH combined with complementary therapy can moderately reduce endocrine therapy-induced side effects, including bone loss and dyslipidemia in patients with HR + breast cancer, revealing the potential role of CMH in treating (HR+) breast cancer. More high-quality RCTs are warranted to further validate the effectiveness and safety of CMH.